M. J. Morris

1.9k citations

30 papers · 1.6k indexed · 1 hit paper · h-index 14

Impact in

Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Screening and Detection
Immunology top 5%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology

Papers in

Oncology 20
- Colorectal Cancer Screening and Detection 9
- Colorectal Cancer Treatments and Studies 7
- Colorectal Cancer Surgical Treatments 6
- Cancer Treatment and Pharmacology 3
Pathology and Forensic Medicine 9
- Genetic factors in colorectal cancer 9

Co-authors: Cameron Platell Barry Iacopetta Fabienne Grieu Nikolajs Zeps Michael Phillips David Joseph Paul Salama B Iacopetta
Journals: Journal of Clinical Oncology (16 papers)The Medical Journal of Australia (2 papers)British Journal of Cancer (1 paper)Clinical Cancer Research (1 paper)Histopathology (1 paper)
Partner nations: Australia United States

In The Last Decade

M. J. Morris

30 papers receiving 1.5k citations

Hit Papers

align trajectories log scale

Tumor-Infiltrating FOXP3 ⁺ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer 2008 · 797 citations

Peers

Countries citing papers authored by M. J. Morris

Since Specialization

Citations

This map shows the geographic impact of M. J. Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. J. Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. J. Morris more than expected).

Fields of papers citing papers by M. J. Morris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. J. Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. J. Morris. The network helps show where M. J. Morris may publish in the future.

Co-authors

The 25 scholars most cited alongside M. J. Morris, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with M. J. Morris Line = papers co-authored together M. J. Morris links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients Journal of Pediatric Surgery ·Sajid Khan, M. J. Morris, Kamran Idrees, Mark Gimbel, Shoshana M. Rosenberg, Zhaoshi Zeng, Fangyong Li, Geliang Gan, Jinru Shia, Michael P. LaQuaglia, Philip B. Paty	2016	76
2	Isolated Nasopharyngeal Castleman Disease: An Uncommon Diagnosis in an Unusual Location SHILAP Revista de lepidopterología ·知樹鈴木, M. J. Morris, René Mercier	2014	1
3	Automated tumor detection on bone scans for treatment response assessment. Journal of Clinical Oncology ·A. Rana, Roert Rupiński, Hanne Birgith Larsen, Martin Auerbach, Sabine Gast-Froehlich, Sondre Thygesen, Dinda Rahmayani, David W. Gjertson, M. J. Morris, Steven M. Larson, Howard I. Scher, Jonathan Goldin	2011	1
4	A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. Journal of Clinical Oncology ·William Kevin Kelly, Susan Halabi, Michael A. Carducci, Daniel J. George, John F. Mahoney, Walter M. Stadler, M. J. Morris, Philip W. Kantoff, J. Paul Monk, Eric J. Small, (unknown)	2010	113
5	Molecular profiling of circulating tumor cells (CTC) in patients with castrate metastatic prostate cancer (CMPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy. Journal of Clinical Oncology ·Daniel C. Danila, Aseem Anand, Clifford C. Sung, M. Leversha, Dana E. Rathkopf, M. J. Morris, Lluís Català Oltra, A. Molina, Martin Fleisher, Howard I. Scher	2010	2
6	HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate resistant prostate cancer (CRPC): Results of phase I/II clinical trial. Journal of Clinical Oncology ·Bruce Montgomery, M. J. Morris, Christopher Ryan, Dwight R. Stickney, James M. Frincke, Chris Reading, John Sarantopoulos, Howard I. Scher	2010	5
7	Tumor-Infiltrating FOXP3 ⁺ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer Journal of Clinical Oncology ·Paul Salama, Michael Phillips, Fabienne Grieu, M. J. Morris, Nikolajs Zeps, David Joseph, Cameron Platell, Barry Iacopetta Hit paper breakdown →	2008	797
8	Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy Journal of Clinical Oncology ·Daniel C. Danila, Dana E. Rathkopf, M. J. Morris, Lluís Català Oltra, 麻記上野, Michel van Bruijnsvoort, Aseem Anand, C. Haqq, Martin Fleisher, Howard I. Scher	2008	22
9	Tumor-Infiltrating Lymphocytes and Perforation in Colon Cancer Predict Positive Response to 5-Fluorouracil Chemotherapy Clinical Cancer Research ·M. J. Morris, Cameron Platell, Barry Iacopetta	2008	98
10	Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu- J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC) Journal of Clinical Oncology ·Scott T. Tagawa, Mathew I. Milowsky, M. J. Morris, Shankar Vallabhajosula, Stanley J. Goldsmith, D. J J Britto, Jason Kaplan, Frédérique Berger, Howard I. Scher, Neil H. Bander, David M. Nanus	2008	26
11	Heterogeneous Staining for Mismatch Repair Proteins during Population-Based Prescreening for Hereditary Nonpolyposis Colorectal Cancer Journal of Molecular Diagnostics ·Muthu Sivaramakrishnan, Fabienne Grieu, M. J. Morris, Jennet Harvey, Colin J.R. Stewart, Lyn Schofield, Jack Goldblatt, Barry Iacopetta	2007	71
12	Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting International Journal of Colorectal Disease ·M. J. Morris, Cameron Platell, Kieran McCaul, Michael Millward, Guy van Hazel, Kumi Moriai, James Trotter, David Ransom, Barry Iacopetta	2007	33
13	Identification of serosal invasion and extramural venous invasion on review of Dukes' stage B colonic carcinomas and correlation with survival Histopathology ·Colin J.R. Stewart, M. J. Morris, Yingping Mao, B Iacopetta	2007	34
14	SURGICAL VOLUME INFLUENCES SURVIVAL IN PATIENTS UNDERGOING RESECTIONS FOR STAGE II COLON CANCERS ANZ Journal of Surgery ·M. J. Morris, Cameron Platell	2007	14
15	Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients British Journal of Cancer ·M. J. Morris, Cameron Platell, Lin Fritschi, B Iacopetta	2007	72
16	Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu- J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC) Journal of Clinical Oncology ·Neil H. Bander, David M. Nanus, Mathew I. Milowsky, M. J. Morris, حمیدة عبد الله عطیة خضرجی, Shankar Vallabhajosula, Stanley J. Goldsmith	2007	2
17	Comparing survival outcomes for patients with colorectal cancer treated in public and private hospitals The Medical Journal of Australia ·M. J. Morris, Barry Iacopetta, Cameron Platell	2007	41
18	Population-based study of prognostic factors in stage II colonic cancer British journal of surgery ·M. J. Morris, Cameron Platell, Yingping Mao, Kieran McCaul, B Iacopetta	2006	76
19	Phase 2 trial of ¹⁷⁷Lutetium (¹⁷⁷Lu) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (¹⁷⁷Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC) Journal of Clinical Oncology ·M. J. Morris, Mathew I. Milowsky, Neeta Pandit‐Taskar, Chaitanya Divgi, 敏夫矢崎, J.M. Valle-Melón, Shankar Vallabhajosula, Stanley J. Goldsmith, Howard I. Scher, David M. Nanus	2006	5
20	Infant/Toddler Feeding Practices of Adolescent Mothers: Ethnic Differences and Intergenerational Involvement Family and Consumer Sciences Research Journal ·Garry Auld, M. J. Morris	1994	13

About M. J. Morris

M. J. Morris is a scholar working on Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Cancer Research, having authored 30 papers that have together received 1.6k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (13 papers), Genetic factors in colorectal cancer (9 papers), Colorectal Cancer Screening and Detection (9 papers), Radiopharmaceutical Chemistry and Applications (7 papers), Colorectal Cancer Treatments and Studies (7 papers), Colorectal Cancer Surgical Treatments (6 papers), Cancer Treatment and Pharmacology (3 papers) and Gastric Cancer Management and Outcomes (3 papers). The work is most often cited by research in Oncology (1.2k citations), Immunology (641 citations), Pathology and Forensic Medicine (294 citations), Cancer Research (186 citations) and Pulmonary and Respiratory Medicine (328 citations). M. J. Morris has collaborated with scholars based in Australia and United States. Frequent co-authors include Cameron Platell, Barry Iacopetta, Fabienne Grieu, Nikolajs Zeps, Michael Phillips, David Joseph, Paul Salama, B Iacopetta, Kieran McCaul and Lin Fritschi. Their work appears in journals such as Journal of Clinical Oncology, The Medical Journal of Australia, British Journal of Cancer, Clinical Cancer Research and Histopathology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact